{
    "clinical_study": {
        "@rank": "33340", 
        "arm_group": [
            {
                "arm_group_label": "Group 1 (RT)", 
                "arm_group_type": "Other", 
                "description": "Period 1: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)\nPeriod 2: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)"
            }, 
            {
                "arm_group_label": "Group 2 (TR)", 
                "arm_group_type": "Other", 
                "description": "Period 1: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)\nPeriod 2: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)"
            }
        ], 
        "brief_summary": {
            "textblock": "1. Investigational Product\n\n             1. Imatinib mesylate tablet 400 mg\n\n             2. Glivec film-coated tablet 100 mg (Comparator)\n\n        2. Expected target disease\n\n             1. chronic myeloid leukemia\n\n             2. Gastrointestinal stromal tumors\n\n        3. Study design : Randomized, open-label, single dose, two-period, two-way, crossover\n           study\n\n             1. 36 healthy subjects, 2 groups (18 subjects/group)\n\n             2. 2 Period (either 1-a(1 tablet) or 1-b(4 tablet))\n\n             3. wash-out period : 14 days\n\n        4. Evaluation on pharmacokinetics(PKs) and safety\n\n             1. PKs : Cmax, AUClast, Tmax, AUCinf, t1/2\n\n             2. safety : adverse events, physical examination, vital sign, ECG, Laboratory test\n\n        5. Statistical method\n\n             1. Demography Characteristics\n\n             2. Pharmacokinetic parameters\n\n             3. Safety data"
        }, 
        "brief_title": "A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Chronic Myeloid Leukemia", 
            "Gastrointestinal Stromal Tumor"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Gastrointestinal Stromal Tumors"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy male volunteers between the ages of 20 to 50 years old\n\n          -  weight more than 55kg and within the range of \u00b120% of ideal body weight (IBW)\n\n          -  having neither congenital/chronic diseases nor pathological symptoms/findings as\n             results of medical examination\n\n          -  doctor determines to be suitable as subjects within 3 weeks ago before administration\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity(or history of hypersensitivity) to medicines including imatinib\n             mesylate\n\n          -  Active Liver Diseases or exceed 1.5 times the normal range of AST, ALT, total\n             bilirubin\n\n          -  Creatinine clearance < 80 mL/min\n\n          -  Gastrointestinal diseases or surgeries that affect absorption of drug\n\n          -  Excessive drinking(exceed 21units/week)\n\n          -  Smoking over 10 cigarettes per day"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01751919", 
            "org_study_id": "Imatinib_CML_I"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 1 (RT)", 
                    "Group 2 (TR)"
                ], 
                "intervention_name": "Imatinib mesylate tablet 400 mg, 1 Tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group 1 (RT)", 
                    "Group 2 (TR)"
                ], 
                "intervention_name": "Glivec film-coated tablet 100 mg, 4 Tablets", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Imatinib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CML", 
            "GIST"
        ], 
        "lastchanged_date": "December 14, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Daegu", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Kyungpook National University"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400 mg (1 Tablet) and Glivec Film-coated Tablet 100 mg (4 Tablets) After Oral Administration in Healthy Male Subjects (Phase I)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea : Korea Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum concentration in plasma (Cmax) of Imatinib mesylate", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose(0h) AND 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 h post-dose"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from zero time until the last measurable concentration (AUClast) of Imatinib mesylate", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose(0h) AND 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 h post-dose"
            }
        ], 
        "reference": [
            {
                "PMID": "19922893", 
                "citation": "Parrillo-Campiglia S, Ercoli MC, Umpierrez O, Rodr\u00edguez P, M\u00e1rquez S, Guarneri C, Estevez-Parrillo FT, Laurenz M, Estevez-Carrizo FE. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. Clin Ther. 2009 Oct;31(10):2224-32. doi: 10.1016/j.clinthera.2009.10.009."
            }, 
            {
                "PMID": "15132131", 
                "citation": "Nikolova Z, Peng B, Hubert M, Sieberling M, Keller U, Ho YY, Schran H, Capdeville R. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chemother Pharmacol. 2004 May;53(5):433-8. PubMed PMID: 15132131."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01751919"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to Cmax (Tmax) of Imatinib mesylate", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose(0h) AND 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 h post-dose"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero to infinity (AUCinf) of Imatinib mesylate", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose(0h) AND 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 h post-dose"
            }, 
            {
                "measure": "Terminal Elimination Half-life (t1/2) of Imatinib mesylate", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose(0h) AND 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 h post-dose"
            }
        ], 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}